<DOC>
	<DOC>NCT01155219</DOC>
	<brief_summary>This phase IV study aims to assess the safety and the efficacy in intra ocular pressure of Geltim LP® 1 mg/g (0.1% unpreserved timolol maleate gel) in glaucomatous patients initially treated and stabilised by monotherapy of Xalatan® with ocular objective signs of intolerance to prostaglandin eye drops.</brief_summary>
	<brief_title>Safety, Efficacy Assessment of Geltim LP® 1 mg/g in Ocular Hypertensive or Glaucomatous Patients.</brief_title>
	<detailed_description>The primary objectives are to compare the safety and the efficacy of Geltim LP® 1mg/g eye drops versus Xalatan® eye drops with respect to: The assessment of the ocular tolerance: - Ocular symptoms - Objective ocular signs. The maintain of the IOP efficient lowering effect. Comparison between the 2 study products of the mean basal IOP after a 12 weeks treatment period (84 days ±7).</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<criteria>Written informed consent. Association of the 4 following criteria: 1. Bilateral primary open angle glaucoma or bilateral ocular hypertension already treated and controlled by monotherapy of Xalatan® (1drop per day), 2. With local intolerance signs. Presence of severe objective ocular sign. Any ocular hypertension other than primary ocular hypertension or primary chronic open angle glaucoma (such as congenital, angle closure glaucoma, secondary glaucoma). Absolute defect in the ten degrees central point of the visual field. Best far corrected visual acuity ≤ 1/10.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Bilateral Glaucoma</keyword>
	<keyword>Bilateral ocular hypertension</keyword>
	<keyword>Bilateral primary open angle glaucoma</keyword>
	<keyword>Bilateral ocular hypertension already treated and controlled by mono-therapy of Xalatan® (1drop per day)</keyword>
	<keyword>With local intolerance signs in at least one eye</keyword>
</DOC>